medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2016, Número 1

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2016; 32 (1)


Protocolo ALLIC-BFM 2002 en el Instituto de Hematologia e Inmunologia: experiencia de 10 años December 21, 2015

González OA, Arencibia NA, Machín GS, Menéndez VA, Gutiérrez DA, Nordet CI, Serrano MJ, Pavón MV, Villatoro VM, Svarch E, Macías AC, Amor VAM, Lavaut SK, Marsán SV, Lam DRM

Idioma: Español
Referencias bibliográficas: 55
Paginas: 70-85
Archivo PDF: 196.85 Kb.


RESUMEN

Introducción: la leucemia linfoide aguda (LLA) es la enfermedad maligna más frecuente en la infancia y la primera que se trató con un protocolo común en Cuba.
Objetivo: presentar los resultados alcanzados en el tratamiento de la LLA con el protocolo del grupo ALLIC-BFM 2002 en el Instituto de Hematología e Inmunología.
Métodos: fueron incluidos 125 pacientes pediátricos tratados en el período comprendido entre enero de 2002 y diciembre de 2011. Se clasificaron en grupos de riesgo de acuerdo con la edad y el número inicial de leucocitos, las alteraciones moleculares y la respuesta al tratamiento.
Resultados: las medianas de seguimiento y edad fueron 5,8 y 5,2 años, respectivamente. Predominó el sexo masculino, relación 1,5:1. La frecuencia de la LLA B fue del 81,3 % y el reordenamiento más común el TEL-AML1 (24,1 %). La respuesta a la profase con prednisona fue favorable en el 95,2 % y se alcanzó remisión inicial en el 91,6 % de los enfermos, con 4,0 % de muertes en la inducción. La sobrevida global y libre de eventos a los 7 años fue del 74,3 % y el 68,9 %, respectivamente; en el grupo de riesgo estándar fue del 84,2 % y el 82,0 %; en el intermedio, del 71,8 % y el 68,5 %; y en el de riesgo alto, del 25,4 % para ambas variables. Al momento de la evaluación, el 75 % de los pacientes estaban en remisión.
Conclusiones: los valores de sobrevida fueron comparables a los alcanzados por otros centros que utilizan protocolos similares.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Pui CH. Acute lymphoblastic leukemia: introduction. Semin Hematol. 2009 Jan;46(1):1-2.

  2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006 Jan 12;354(2):166-78.

  3. González A, Vergara B. Las leucemias en pediatría. En: Pediatría III. La Habana: Pueblo y Educación; 1997. p. 25-31.

  4. Conter V, Arico M, Basso G, Biondi A, Barisone E, Messina C, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010 Feb;24(2):255-64.

  5. Gandemer V, Auclerc MF, Perel Y, Vannier JP, Le Gall E, Demeocq F, et al. Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. BMC Cancer. 2009;9:14.

  6. Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000 Dec;14(12):2247-56.

  7. Pui CH, Mulligan CG, Evans W, Reiling MV, Ribeiro RC, Howard SC, et al. Pediatric Acute lymphoblastic leukemia : Where are we going and how do we get there. Blood. 2012:120 (6):1165-74.

  8. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, et al. Longterm results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010 Feb;24(2):320-34.

  9. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia. 2002 Jun;16(6):1099-111.

  10. Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gardner H, et al. Long term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the BFM ALL study group from 1981 to 2000. Leukemia. 2010;24(2):265-64.

  11. Svarch E, González A, Lagarde M, Vergara B. Tratamiento de la LLA del niño. Bol Med Hosp Infantil México. 1980;37:707-14.

  12. Svarch E, González A, Vergara BC, Campo M, Méndez J, Fernández O, et al. Tratamiento de la leucemia linfoide aguda ( LLA) en el niño. Sangre. 1993;38:251-7.

  13. González-Otero A, Menéndez-Veitía A, Machín-García S, Svarch E, Campo-Díaz M, Fernández-Nodarse R, et al. Resultados del tratamiento de la leucemia linfoide aguda del niño en Cuba. Rev Cubana Hematol Inmunol Hemoter. 2014 Dic;30(1):36-46.

  14. Biondi A, Baruchel A, Hunger S, Masera G, Schmiegelow K, Schrappe M, et al. The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009. Leukemia. 2009 Dec;23(12):2318-24.

  15. Arico M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, et al. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt- Muenster based chemotherapy. J Clin Oncol. 2008 Jan;26(2):283-9.

  16. Olah E, Balogh E, Pajor L. Jakar Z and the Hungarian Pediatric Oncology network: Ten years experiences on initial genetic examinations in childhood acute lymphoblastic leukemia in Hungary (1993-2002). Technical approaches and clinical implementation. Pathol Oncol Res. 2011;17(1):81-90.

  17. Pui CH, Carrol W, Mechinhi L, Arceci RJ. Biology risk stratification and therapy of pediatric acute lymphoblastic leukemia: An update. J Clin Oncol. 2011;29(5):551-6.

  18. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia. 2010 Feb;24(2):285-97.

  19. Solano-Genesta M, Tarh-Arzaga L, Velasco-Ruiz I, Lutz-Presno JA, Gonzalez-LLano Q, Macias-Guerra C, et al. CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia is common in mexican patients and lacks a prognostic value Hematology. J Pediatr Hematol Oncol. 2012; 17(2):66-70.

  20. Te WinkelML, Peters R, Wind EJ, Bessen s JH, van der Heuvel-Ebrink MM. Management and treatment of osteonecrosis in chidren and adolescents with acute lymphoblastic leukemia. Haematologica. 2014;99(3):430-6.

  21. Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood. 2010 Jun;115(24):4999-5004.

  22. Raja RA, Schmlegelow K, Frandsen TL. Asparaginase associated pancreatitis in children. Br J Haematol. 2012;159(1):18-27.

  23. Schultz KR, Devides M, Bowman WP, Aledo A, Slayten WB, Sather H, et al. Philapelphia chromosome negative very high risk acute lymphoblastic leukemia in children and adolescents Results from the Children's Oncology Group study AALL 0031. Leukemia. 2014;28(4):964-7.

  24. Lauter M, Moricke A, Beller R, Zimmermann M, Stamuller M, Helssnter A, et al. Prediction of outcome asessed by early bone marrow response in childhood acute lymphoblastic leukemia treated by ALL BFM 95. Differential effects in precursor B cell and in T cell leukemias. Haematologica. 2012;97(7):1048-56.

  25. Sirvent N, Suciu S, RiallandK, Millot F, Benoit Y, Plantaz D, et al. Prognostic significance ot the initial cerebrospinal fluid (CSF)involvement in children with acute lymphoblastic leukemia (ALL)treated without cranial irradiation Results of the European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group Study 5888. Eur J Cancer. 2011;67(2):289-47.

  26. Liang DC, Yang CP, Lin DT, Hung IJ, Lin KH, Chen JS, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia. 2010 Feb;24(2):397-405.

  27. Reddick WE, Taghpour DJ, Glass JD, Ashford Jj, Xiong X, Wu S, et al. Prognostic factors that increase the risk for reduced white matter volumen and deficits in attention and learning for survivors of childhood cancers. Pediatr Blood Cancer. 2014;61(6):1074-9.

  28. Jaime-Fagundo JC, Arencibia-Núñez A, Gutiérrez-Díaz A, Ramón-Rodríguez L, Díaz-Durán C. Urgencias en Hematología: alteraciones metabólicas y leucocitarias. Rev Cubana Hematol Inmunol Hemoter. 2012 Mar;28(1):3-21.

  29. Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, et al. Improved results for older adolescents with acute lymphoblastic leukemia. J Clin Oncol. 2011;29(4):386-91.

  30. Rubnitz JE, Wichlan D, Devidas M, Shuster J, Linda SB, Kurtzberg J, et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2008 May 1;26(13):2186-91.

  31. Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010 Jan;95(1):87-95.

  32. Sam TN, Kersey JH, Linaberry AM, Reston K. MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: A Children's Oncology Group (COG) survey . Pediatr Blood Cancer. 2012;58(6):636-9.

  33. Bhatia S. Disparities in cancer outcome. Lessons learned from children with cancer. Pediatr Blood Cancer. 2012:56(5):994-1002.

  34. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009 Jan;360(5):470-80.

  35. Pui CH. T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome. Cancer Cell. 2009 Feb 3;15(2):85-7.

  36. Sorich MJ, Pottier N, Pei D, Yang W, Kager L, Stocco G, et al. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med. 2008 Apr 15;5(4):e83.

  37. Manabe A, Ohara A, Hasegawa D, Tsuchida M, Kumagai M, Shimada H, et al. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15. Haematologica. 2008 May;93(8):1155-60.

  38. Flotho C, Coustan-Smith E, Pei D, Cheng C, Song G, Pui CH, et al. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood. 2007 Aug;110(4):1271-7.

  39. Olsson L, Castor A, Behrendtz M, Biloglav A, Forrester E, Paulsson K, et al. Deletions of IKZF-1 and SPRED -1 are associated with poor prognosis pn a population based series of pediatric B cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia. 2014;28(2):302-10.

  40. Gandemer V, Chevret S, Petit A, Vermylen C, Leblanc T, Michel C, et al. Excellent prognosis of late relapses of ETV6! Runx1positive childhood acute lymphoblastic leukemia Lessons from the FRALLE 93 protocol. Haematologica. 2012;97(11):1743- 50. doi 103324haematol 2011.

  41. Conter V, Valsecchi MG, Parasie R, Puti MC, Locatelli F, Barisone E, et al. Childhood high risk acute lymphoblastic leukemia in first remission results after chemotherapy or transplant from the AIEOP 2000 study. Blood. 2014;120(10):1470-8.

  42. Buendia MT, Lozano JM, Suarez GE, Saavedra C, Guevara G. The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia. J Pediatr Hematol Oncol. 2008 Sep;30(9):643-50.

  43. Ribera JM, Oriol A, Morgades M, Montesino S, Perma J, Gonzalez-Campos J, et al. Treatment of high risk Philadelphia chromosome negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry. Final results of the PETHEMA ALL-AR-93 trial. J Clin Oncol. 2014;32(15):1595-604.

  44. Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010 May;28(14):2339-47.

  45. Nguyen K, Devidas M, Cheng SC, Su X, Zhang J, Cao X, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008;22(12):2142-50.

  46. Stary J, Gajdos P, Blazek B, Ptoszkova H, Mihal V, Pospisilova D, et al. Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic. Cas Lek Cesk. 2003;142(7):404-9.

  47. Pastorczak AF, Fendler W, Zalewska-Szewckyk B, Gomiak P, Neiman M, Trelwska J, et al. Polish Pediatric Leukemia/Lymphoma Study Group. Asparagine synthetase (ASNS) gene polymorphim is associated with the outcome of childhood acute lymphoblastic leukemia affecting early response to treatment. Leuk Res. 2014 Feb;38(2):160-3.

  48. Rives S, Estella J, Camos M, Garcia-Miguel P, Verdeguer A, Couselo JM, et al. T cell pediatric acute lymphoblastic leukemia. Analysis of survival and prognostic factors in four consecutive protocols of the spanish cooperative group (SHOP). Med. Clin (Barc). 2012 jul;139(4):141-9.

  49. Talen G, Patel R, Mann G, Kaspers G, Niggl F, Karachuns A, et al. Long-term outcomes in children with relapsed acute lymphoblastic leukaemia after time-point and site of relapse stratification and intensified short courses of multidrug chemotherapy. Results of ALL-REZ BFM 90. J Clin Oncol. 2010;28(14):2339-47.

  50. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010 Apr 29;115(17):3437-46.

  51. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia. 2000 Dec;14(12):2276-85.

  52. Tsuchida M, Ohara A, Manabe A, Kumagai M, Shimada H, Kikuchi A, et al. Longterm results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia. 2010 Feb;24(2):383-96.

  53. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010 Feb;24(2):371-82.

  54. Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002. J Clin Oncol. 2014 Jan;32(3):174-85.

  55. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010 Feb;24(2):309-19.




2020     |     www.medigraphic.com